Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ongentys

- PMLiVE

EC approves Atara and Pierre Fabre’s Ebvallo as monotherapy for Epstein-Barr patients

The approval is for adults and those over two years old with relapsed or refractory EBV+PTLD

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced gastric cancer

Approximately 136,000 cases of gastric cancer are diagnosed annually in Europe

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

- PMLiVE

Boehringer’s Spevigo receives EC approval for generalised pustular psoriasis flares

Trial showed 54% of patients were free of pustules one week after a single dose

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma

Results continue to show significant reduction in risk of death for DLBCL patients

- PMLiVE

Takeda’s dengue vaccine receives EC approval

The decision follows a positive recommendation for Qdenga from the CHMP in October

- PMLiVE

WHO and EC expand strategic plans to deliver better health security

The partnership will reinforce areas highlighted in the EU Global Health Strategy

- PMLiVE

Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations

After changing to Biktarvy, 98% of patients in two groups were suppressed at week 48

- PMLiVE

MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis

The changes to the terms were also approved by the EC in October

- PMLiVE

Precision medicine trial opens for patients with rare cancers

Rare cancers make up 22% of cancers that are diagnosed globally each year, more than any single type of cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links